Related Experiment Video
Updated: Jun 13, 2025
07:47
Author Spotlight: Unveiling Transmembrane Protein Family-Related Markers in Gastric Cancer and Implications for Targeted Therapies
Published on: September 15, 2023
1.4K
RBM10 Is a Biomarker Associated with Pan-Cancer Prognosis and Immune Infiltration: System Analysis Combined with In
Yingyue Cao1, Luyi Pang2, Shi Jin1
1National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital and Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen 518116, China.
Oxidative Medicine and Cellular Longevity
|September 16, 2024
Summary
RNA binding motif protein 10 (RBM10) impacts cancer prognosis and immune response across many cancer types. Its expression and mutations correlate with tumor progression and drug sensitivity, offering potential as an immunotherapy biomarker.
Area of Science:
- Oncology
- Immunology
- Genetics
Background:
- RNA binding motif protein 10 (RBM10) is a splicing factor implicated in various cancers.
- Its specific role in pan-cancer immunotherapy remains largely uncharacterized.
Purpose of the Study:
- To comprehensively assess the prognostic value and immunological function of RBM10 in human pan-cancer.
- To investigate RBM10's association with clinical outcomes, tumor progression, and immune landscape.
Main Methods:
- Utilized multiple public databases for pan-cancer analysis.
- Examined RBM10 expression, mutation frequency, and correlation with clinical prognosis.
- Assessed RBM10's link to immune checkpoints, tumor-infiltrating lymphocytes, tumor mutation burden, and microsatellite instability.
- Conducted in vitro and in vivo experiments to validate RBM10's functional role and PD-L1 regulation.
Main Results:
- Aberrant RBM10 expression observed in most tumors, with variable prognostic implications.
- Frequent RBM10 mutations associated with tumor progression.
- RBM10 significantly correlated with immune checkpoints, tumor immune infiltration, TMB, and MSI.
- RBM10 expression linked to sensitivity of specific targeted therapies and potential drug resistance.
- Downregulation of RBM10 promoted lung adenocarcinoma malignancy; overexpression inhibited tumor growth.
- RBM10 modulated PD-L1 protein levels and stability.
Conclusions:
- RBM10 serves as a potential prognostic biomarker across various cancers.
- RBM10 influences the tumor immune microenvironment and may impact immunotherapy response.
- RBM10 modulation affects cancer cell phenotype and tumor growth, highlighting its therapeutic relevance.
